A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...

CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were down ...

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.